In addition, our results have a practical tone, indicating that to assess the immunomodulatory function of ASCs from SLE and SSc patients, it is better to study the effector phases of Th differentiation process than analyse it at the transcriptional level and to use PBMCs rather than CD4+ T cells as the target cells. Here, CD4 is linked to systemic sclerosis.